• Media
• Register for Updates
• Contact Us

• 
  • Overview
  • Management
  • Board of Directors
  • Governance
  • Collaborations
• 
  • SRMs
  • SERMs
  • SARMs
  • Technology FAQs
• 
  • Overview
  • Toremifene 80 mg
  • Toremifene 20 mg
  • Ostarine™
  • GTx-758
  • Clinical Trials
• 
  • Fareston^®
• 
  • Investor Relations
  • Stock Information
  • Fundamentals
  • Event Calendar
  • Financial Reports
  • Estimates & Analysts
  • SEC Filings
  • Governance
  • Investor FAQs
  • Email Alerts
  • Information Request
  • News Releases
• 
  • Overview
  • Current Opportunities
  • Benefits
  • Employee Perspectives
  • Living & Working in Memphis
  • College Internships

• J. R. Hyde, III, Chairman
• Mitchell S. Steiner, M.D., F.A.C.S., Vice Chairman and Chief Executive Officer
• Marc S. Hanover, President and Chief Operating Officer
• Michael G. Carter, M.D.
• J. Kenneth Glass
• Robert W. Karr, M.D.
• John H. Pontius
• Kenneth S. Robinson, M.D., M.Div.
• Timothy R. G. Sear

J. R. Hyde, III, Chairman. Mr. Hyde, age 66, has served as the Chairman of our Board of Directors since November 2000 and currently serves as Chairman of the Compensation Committee. Since 1989, Mr. Hyde has been the sole stockholder and President of Pittco Holdings, Inc., a private, institutional investment company. Since 1996, when Mr. Hyde made a substantial contribution to support Dr. Steiner’s research, Mr. Hyde has been instrumental in forming and financing GTx and is our largest stockholder. Mr. Hyde was the Chairman of the Board of Directors of AutoZone, Inc. (NYSE: AZO) from 1986 to 1997 and the Chief Executive Officer of AutoZone from 1986 to 1996. He was also Chairman and Chief Executive Officer of Malone & Hyde, Inc., AutoZone’s former parent company, from 1972 until 1988. Mr. Hyde is a director of AutoZone, Inc. and FedEx Corporation (NYSE: FDX). In March 2005, Mr. Hyde was appointed as the non-executive Chairman of the Board of Directors of AutoZone, Inc.

Mitchell S. Steiner, M.D., F.A.C.S., Vice Chairman and Chief Executive Officer. Dr. Steiner, age 48, a co-founder of GTx, has served as the Vice Chairman of our Board of Directors and our Chief Executive Officer since the Company's inception in September 1997. From 1995 to 2003, Dr. Steiner held numerous academic appointments, including Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee. Since 2003, Dr. Steiner has continued to serve on the faculty at the University of Tennessee. Dr. Steiner holds a B.A. in Molecular Biology from Vanderbilt University, an M.D. from the University of Tennessee and performed his surgery and urologic training at The Johns Hopkins Hospital.

Marc S. Hanover, President and Chief Operating Officer. Mr. Hanover, age 46, a co-founder of GTx, has served as our President and Chief Operating Officer and as a director since the Company's inception in September 1997. Prior to joining GTx, Mr. Hanover was a founder of Equity Partners International, Inc., a private equity firm in Memphis, Tennessee, and participated as a founder and investor in three healthcare companies. From 1985 to 1997, Mr. Hanover was a Senior Vice President and a member of the Executive Management Committee of National Bank of Commerce in Memphis, Tennessee. Mr. Hanover holds a B.S. in Biology from the University of Memphis and an MBA in Finance from the University of Memphis.

Michael G. Carter, M.D., age 70, was appointed to the Board of Directors in May 2006 and is a member of the Compensation Committee. Dr. Carter currently is a non-executive director of Micromet, Inc.; Santarus, Inc.; and Fulcrum Pharma plc. He is non-executive chairman of Metris Therapeutics, Ltd., a biotechnology firm specializing in women's healthcare. He is a member of the Advisory Board of Paul Capital Royalty Fund and is a venture partner with SV Life Sciences Advisers, LLP. He served on the Pharmaceutical Board of Zeneca Pharmaceuticals, a predecessor company of AstraZeneca, and held various positions within Zeneca, including International Marketing Director and International Medical Director. Under his direction, Zeneca developed and launched numerous drugs, including Casodex^®, the most widely prescribed anti-androgen for prostate cancer therapy in the U.S.; Zoladex^®, an LHRH analogue for prostate cancer and breast cancer; and Arimidex^®, the first new generation aromatase inhibitor for breast cancer. Dr. Carter also contributed to the post marketing development of tamoxifen, the first selective estrogen receptor modulator approved for the treatment of breast cancer. Dr. Carter received his medical degree from Sheffield University Medical School and a BPharm degree from the London University School of Pharmacy. He is a Fellow of the Royal Pharmaceutical Society, of the Royal College of Physicians of Edinburgh and of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He has served as a member of the Medicines Commission of the United Kingdom.

J. Kenneth Glass, age 62, has served as a director since March 2004 and currently serves on the Audit Committee as Chairman and on the Compensation Committee. Mr. Glass was until 2007, Chairman of the Board, President and Chief Executive Officer of First Horizon National Corporation (“First Horizon”) (NYSE: FHN) and First Tennessee Bank National Association (“First Tennessee Bank”). Mr. Glass was elected Chairman of the Board of First Horizon effective January 1, 2004, and President and Chief Executive Officer of First Horizon in July 2002. Mr. Glass received his B.A. in Accounting from Harding University and graduated from Harvard Business School’s Advanced Management Program.

Robert W. Karr, M.D., age 60, has served as a director since June 2005 and currently serves on the Nominating and Corporate Governance Committee. Dr. Karr served as President of Idera Pharmaceuticals, Inc. from December 2005 through December 2007, and he currently serves on its Board of Directors (AMEX: IDP). From 2000 to 2004, Dr. Karr was a senior executive for Global Research & Development for Pfizer, Inc., where he served as Senior Vice President, Strategic Management from 2003 to 2004. Prior to its merger with Pfizer (NYSE: PFE), Dr. Karr served as Vice President, Research & Development Strategy for Warner Lambert Company. Dr. Karr received his B.S. (with honors) from Southwestern University in 1971 and his M.D. from the University of Texas Medical Branch in 1975. Dr. Karr completed his internship and residency in internal medicine at Washington University School of Medicine and served as a faculty member at both the University of Iowa College of Medicine and Washington University School of Medicine.

John H. Pontius, age 53, has served as a director since April 1998 and currently serves as Chairman of the Nominating and Corporate Governance Committee. Mr. Pontius has been the President of Pittco Management, LLC, since 1991. From 1986 to 1991, Mr. Pontius served as the Chief Financial Officer of the City of Memphis, Tennessee. Mr. Pontius holds a B.S. in Accounting from the University of Tennessee. Mr. Pontius served as a member of the Board of Trustees of the University of Tennessee from 2002 to 2004.

Kenneth S. Robinson, M.D., M.Div., age 54, has served as a director since May 2008 and serves as a member of the Nominating and Corporate Governance Committee. From 2003 through 2007, Dr. Robinson served in the cabinet of Tennessee Governor Phil Bredesen as Commissioner of Health, overseeing 3,500 state employees and a $548 million budget. From 1982 through 1991, Dr. Robinson taught and practiced internal medicine at Vanderbilt University School of Medicine, and from 1991 through 2003 he was an Assistant Dean at the University of Tennessee College of Medicine. Since 1991, he has served as Pastor and Chief Executive of St. Andrew AME Church. In 1998, Dr. Robinson was named one of the country's ten Community Health Leaders by the Robert Wood Johnson Foundation, and in 2000 he received the Community Builder Award from the national United Way of America. Dr. Robinson holds a B.A., cum laude, from Harvard University, a M.D. from Harvard Medical School and a Master of Divinity from Vanderbilt Divinity School.

Timothy R. G. Sear, age 71, was appointed as a director in October 2004 and currently serves on the Audit Committee and the Compensation Committee. Mr. Sear currently serves as Chairman Emeritus of Alcon, Inc., having retired from the offices of President and Chief Executive Officer on September 30, 2004. Prior to serving as President and Chief Executive Officer of Alcon, Mr. Sear served as Executive Vice President for U.S. Operations from 1996 through 1997 and also as Executive Vice President for Alcon’s International Division from 1988 to 1996. Mr. Sear is a graduate of Manchester University in the UK and Copenhagen University, Denmark, and received an MBA in International Business from Indiana University. He is also a graduate of Harvard Business School’s Advanced Management Program. Mr. Sear is a director of Sigma-Aldrich, Inc. (Nasdaq: SIAL).